0253 GMT - Raffles Medical shares' risk-reward profile appears attractive, says RHB Research's Shekhar Jaiswal in a note, citing its widening discount, compared with its Southeast Asian peers, and net-cash balance sheet. The Singaporean hospital operator's shares have fallen to a 52-week low following its soft 1H results, he says. Yet, the right-sizing of its transitional care facility, reflected in the results, suggests normalization rather than a deterioration of its core healthcare franchise, he says. The analyst views the company's China segment as a medium-term growth driver, with the potential break-even of its Shanghai facility likely to be a catalyst. RHB retains its buy rating and its target price of 1.15 Singapore dollars. Shares are down 0.6% at S$0.83.